| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial
|
Bruix, Jordi
|
|
2015
|
16 |
13 |
p. 1344-1354
11 p.
|
artikel
|
| 2 |
Adjuvant sorafenib for liver cancer: wrong stage, wrong dose
|
Kelley, Robin Kate
|
|
2015
|
16 |
13 |
p. 1279-1281
3 p.
|
artikel
|
| 3 |
Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial
|
Burnett, Alan K
|
|
2015
|
16 |
13 |
p. 1295-1305
11 p.
|
artikel
|
| 4 |
A tale of regeneration
|
Brogan, Caroline
|
|
2015
|
16 |
13 |
p. 1293-
1 p.
|
artikel
|
| 5 |
Cannabis and cancer: reality or pipe dream?
|
Cathcart, Paul
|
|
2015
|
16 |
13 |
p. 1291-1292
2 p.
|
artikel
|
| 6 |
Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial
|
Grob, Jean Jacques
|
|
2015
|
16 |
13 |
p. 1389-1398
10 p.
|
artikel
|
| 7 |
Controversy about UK assisted dying bill
|
Burki, Talha Khan
|
|
2015
|
16 |
13 |
p. e483-
1 p.
|
artikel
|
| 8 |
Corrections to multiple conflicts of interest statements
|
|
|
2015
|
16 |
13 |
p. e480-
1 p.
|
artikel
|
| 9 |
Correction to Lancet Oncol 2015; 16: 1289
|
|
|
2015
|
16 |
13 |
p. e480-
1 p.
|
artikel
|
| 10 |
Correction to Lancet Oncol 2015; 16: 1338
|
|
|
2015
|
16 |
13 |
p. e480-
1 p.
|
artikel
|
| 11 |
Correction to Lancet Oncol 2015; 16: e434
|
|
|
2015
|
16 |
13 |
p. e480-
1 p.
|
artikel
|
| 12 |
28 days from referral to diagnosis in the UK: is it possible?
|
Burki, Talha Khan
|
|
2015
|
16 |
13 |
p. e485-
1 p.
|
artikel
|
| 13 |
Discordance between the results and conclusions of ICON7
|
Gyawali, Bishal
|
|
2015
|
16 |
13 |
p. e478-
1 p.
|
artikel
|
| 14 |
Discordance between the results and conclusions of ICON7 – Authors' reply
|
Oza, Amit M
|
|
2015
|
16 |
13 |
p. e478-e479
nvt p.
|
artikel
|
| 15 |
Disease kinetics for decision-making in advanced melanoma: a call for scenario-driven strategy trials
|
Grob, Jean Jacques
|
|
2015
|
16 |
13 |
p. e522-e526
nvt p.
|
artikel
|
| 16 |
Dose-limiting toxicity and maximum tolerated dose: still fit for purpose?
|
Wong, Han Hsi
|
|
2015
|
16 |
13 |
p. 1287-1288
2 p.
|
artikel
|
| 17 |
Ductal carcinoma in situ and breast cancer mortality
|
Tanday, Sanjay
|
|
2015
|
16 |
13 |
p. e481-
1 p.
|
artikel
|
| 18 |
E-cigarettes and subsequent tobacco use in adolescence
|
Baker, Holly
|
|
2015
|
16 |
13 |
p. e481-
1 p.
|
artikel
|
| 19 |
Enterovirus infection and childhood leukaemia: an association?
|
Spector, Logan G
|
|
2015
|
16 |
13 |
p. 1278-1279
2 p.
|
artikel
|
| 20 |
Evolving treatment options for melanoma brain metastases
|
Ajithkumar, Thankamma
|
|
2015
|
16 |
13 |
p. e486-e497
nvt p.
|
artikel
|
| 21 |
Expansion platform type II: testing a treatment strategy
|
Catenacci, Daniel V T
|
|
2015
|
16 |
13 |
p. 1276-1278
3 p.
|
artikel
|
| 22 |
FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study
|
Cremolini, Chiara
|
|
2015
|
16 |
13 |
p. 1306-1315
10 p.
|
artikel
|
| 23 |
Hello. I have cancer. How are you?
|
Harding, Emilia
|
|
2015
|
16 |
13 |
p. 1294-
1 p.
|
artikel
|
| 24 |
HPV vaccination not linked to miscarriage
|
Tanday, Sanjay
|
|
2015
|
16 |
13 |
p. e485-
1 p.
|
artikel
|
| 25 |
International Liver Cancer Association Annual Conference
|
Lokody, Isabel
|
|
2015
|
16 |
13 |
p. 1289-
1 p.
|
artikel
|
| 26 |
Is UK cancer care broken?
|
The Lancet Oncology,
|
|
2015
|
16 |
13 |
p. 1273-
1 p.
|
artikel
|
| 27 |
Lack of access to targeted cancer therapy
|
Burki, Talha Khan
|
|
2015
|
16 |
13 |
p. e482-
1 p.
|
artikel
|
| 28 |
Locoregional treatment versus no treatment of the primary tumour in metastatic breast cancer: an open-label randomised controlled trial
|
Badwe, Rajendra
|
|
2015
|
16 |
13 |
p. 1380-1388
9 p.
|
artikel
|
| 29 |
Maintenance strategies after first-line oxaliplatin plus fluoropyrimidine plus bevacizumab for patients with metastatic colorectal cancer (AIO 0207): a randomised, non-inferiority, open-label, phase 3 trial
|
Hegewisch-Becker, Susanna
|
|
2015
|
16 |
13 |
p. 1355-1369
15 p.
|
artikel
|
| 30 |
Maintenance therapy for metastatic colorectal cancer
|
Giampieri, Riccardo
|
|
2015
|
16 |
13 |
p. 1281-1282
2 p.
|
artikel
|
| 31 |
Me and Earl and the Dying Girl
|
Cleghorn, Sean
|
|
2015
|
16 |
13 |
p. 1292-1293
2 p.
|
artikel
|
| 32 |
Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial
|
Le Tourneau, Christophe
|
|
2015
|
16 |
13 |
p. 1324-1334
11 p.
|
artikel
|
| 33 |
MRI study identifies three subtypes of glioblastoma
|
Brower, Vicki
|
|
2015
|
16 |
13 |
p. e484-
1 p.
|
artikel
|
| 34 |
Mutation and location important in cancer treatment
|
Lewis, Ricki
|
|
2015
|
16 |
13 |
p. e482-
1 p.
|
artikel
|
| 35 |
Ofatumumab maintenance versus observation in relapsed chronic lymphocytic leukaemia (PROLONG): an open-label, multicentre, randomised phase 3 study
|
van Oers, Marinus H J
|
|
2015
|
16 |
13 |
p. 1370-1379
10 p.
|
artikel
|
| 36 |
Older people not likely to refuse cancer treatment
|
Bagcchi, Sanjeet
|
|
2015
|
16 |
13 |
p. e483-
1 p.
|
artikel
|
| 37 |
PD-L1 expression as a potential predictive biomarker
|
Fusi, Alberto
|
|
2015
|
16 |
13 |
p. 1285-1287
3 p.
|
artikel
|
| 38 |
PROLONGing remissions in patients with CLL
|
Wiestner, Adrian
|
|
2015
|
16 |
13 |
p. 1282-1284
3 p.
|
artikel
|
| 39 |
Radiation and checkpoint blockade immunotherapy: radiosensitisation and potential mechanisms of synergy
|
Sharabi, Andrew B
|
|
2015
|
16 |
13 |
p. e498-e509
nvt p.
|
artikel
|
| 40 |
Removing the primary tumour in metastatic breast cancer
|
Cameron, David
|
|
2015
|
16 |
13 |
p. 1284-1285
2 p.
|
artikel
|
| 41 |
Risk of death among children of atomic bomb survivors after 62 years of follow-up: a cohort study
|
Grant, Eric J
|
|
2015
|
16 |
13 |
p. 1316-1323
8 p.
|
artikel
|
| 42 |
Risk of leukaemia in children infected with enterovirus: a nationwide, retrospective, population-based, Taiwanese-registry, cohort study
|
Lin, Jiun-Nong
|
|
2015
|
16 |
13 |
p. 1335-1343
9 p.
|
artikel
|
| 43 |
Should we worry about inherited radiation risks?
|
Brenner, David J
|
|
2015
|
16 |
13 |
p. 1275-1276
2 p.
|
artikel
|
| 44 |
Targeting brain metastases in ALK-rearranged non-small-cell lung cancer
|
Zhang, Isabella
|
|
2015
|
16 |
13 |
p. e510-e521
nvt p.
|
artikel
|
| 45 |
16th World Conference on Lung Cancer
|
Landman, Allison
|
|
2015
|
16 |
13 |
p. 1290-
1 p.
|
artikel
|
| 46 |
Time to abandon traditional chemotherapy for acute promyelocytic leukaemia?
|
Ravandi, Farhad
|
|
2015
|
16 |
13 |
p. 1274-1275
2 p.
|
artikel
|
| 47 |
Vemurafenib for relapsed or refractory hairy-cell leukaemia
|
Baker, Holly
|
|
2015
|
16 |
13 |
p. e484-
1 p.
|
artikel
|
Tijdschrift beschrijving